Member Info for draft

this company doesnt have the cash to do this project does it? so its going to need to raise in my opinion

to hang around for 6 months

maybe hes the one in bed with kite and polygon

you just dont know

$30 million to Sanofi

How this vaccine works: Sanofi?also starts with a gene that provides the blueprint for the spike. They take that gene and insert it into a virus called the baculovirus, and then infect an insect cell with that virus. Because of the inserted coronavirus gene, the insect cell then makes the spikes. The vaccine contains those spikes along with a second part, an adjuvant containing Vitamin E, which helps the immune system do its job. Your immune system then makes antibodies to the spikes.

Status: Sanofi expects to start clinical trials between October and December of this year.

History: This same technology using a baculovirus was used to make a flu vaccine called Flublok, which was approved by the FDA in 2013. Several other vaccines, including ones against hepatitis B and HPV, use the same technology, but use other techniques in place of the baculovirus.

If you’ve been following along, you’ll notice that this adds up only to about $2.2 billion, not the $3 billion we mentioned. The US government is awarding about $783 million to three companies to manufacture whichever COVID vaccines get approved by the FDA: Emergent BioSolutions, SiO2 Materials Science, and Ology Bioservices.

$60 million to Novavax
This vaccine involves putting the genetic blueprint for the spike into a virus that infects insects, called a baculovirus. They allow the baculovirus to infect insect cells, which causes the cells to start producing large quantities of the spike. The scientists then put the spikes on top of a very small particle called a nanoparticle. That nanoparticle with the spikes on top is the first part of the vaccine. The second part of the vaccine is a substance called an adjuvant, which is made out of a molecule found in tree bark and food additives. When it’s injected into the body, the immune system recognizes the adjuvant as a foreign substance, and goes into high alert, looking for an infection. What it finds is the nanoparticle with the coronavirus spikes on top. Your immune system then makes antibodies to the spikes.
Status: Novavax has not yet started human clinical trials.

$38 million to Merck

Like AstraZeneca and Johnson & Johnson, Merck uses a virus as a delivery vehicle. This virus is called vesicular stomatitis and it causes flu-like symptoms, but Merck modifies and weakens it so it won’t get you sick. Scientists insert a gene into the virus that contains instructions for making the spikes. The virus is injected and replicates in your body, and because of the inserted gene, you make the spikes. Your immune system then makes antibodies to the spikes.
Status: Merck has not yet started human clinical trials.
History: This same technology was used to make an Ebola vaccine called ERVEBO that was approved by the FDA in 2019.

Hears of the Nuvec delivery system
$1.2 billion to AstraZeneca
How this vaccine works: AstraZeneca is using an adenovirus as a delivery vehicle. Adenoviruses cause the common cold and other illnesses, but the AstraZeneca vaccine alters the adenovirus so it won’t cause harm. Inside the adenovirus, the scientists have tucked away genetic material that codes for the production of those red spikes. The virus is injected, and because of the inserted gene, your cells make the spikes. Your immune system then makes antibodies to the spikes.Status: The University of Oxford, which is partnering with AstraZeneca, recently began large-scale, Phase 3 human clinical trials in England on this vaccine. AstraZeneca plans to begin Phase 3 trials in August. Such trials are the last step before a vaccine maker seeks approval from regulators.History: Other vaccines have used this adenovirus technique, and while those vaccines have been studied in clinical trials, they’ve never been approved and put on the market.
$456 million to Johnson & Johnson
How this vaccine works: J&J’s vaccine also uses an adenovirus delivery vehicle.
Status: J&J expects to start Phase 3 clinical trials in September.

$430 million to Moderna

How this vaccine works: Remember those gumball machines you loved as a kid, the ones in restaurant lobbies? Sometimes right next to them there were machines that delivered little toys, like a tiny doll or a bouncy ball, and the toy came in a little plastic bubble. Insert the quarter and you get the toy delivered in the plastic bubble. Now imagine that this plastic bubble is made out of fat. That’s the delivery system for this vaccine. Instead of a toy, inside that hollow ball of fat is messenger RNA, or mRNA, which is a genetic recipe for making part of the red spike. The fat bubble knows where to deliver it. Your immune system then makes antibodies to the spikes.

Status: Moderna plans to start Phase 3 trials in July.

History: Other vaccines have used this technique, and while those vaccines have been studied in clinical trials, they’ve never been approved and put on the market.

Deleted my posts

when the markets going to realise this mcap is stupidly low.

Innovate UK will provide over EUR 2 million in funding to a promising R&D project, namely “Rare Earth Recycling for E-machines” (RaRE). The venture is led by Mkango Resources Ltd. and is hoped to enable the use of recycled magnets in electric cars.
The project relies on a patented process for extracting and demagnetising neodymium iron boron alloy powders from magnets embedded in scrap and redundant equipment. This novel method is called hydrogen processing of magnet scrap (HPMS). It was originally developed by researchers at the University of Birmingham.

https://drivesncontrols.com/news/fullstory.php/aid/6397/UK_project_aims_to_recycle_rare-earths_for_use_in_new_motors.html

n addition to HyProMag, the project members are:
• the motor designer Advanced Electric Machines Research, whose customers include Airbus and Tevva Motors;
• the luxury car-maker, Bentley Motors, which is part of the VW group;
• the electronics waste processor, Intelligent Lifecycle Solutions; and
• the automotive supplier, Unipart Powertrain Applications.
“We are very excited about this innovative project and the opportunity to scale up and commercialise the HPMS technology,” says Mkango’s CEO, William Dawes. “We envisage that recycling of rare-earth magnets will play a key role in the development of robust supply chains to catalyse and support growth in the electric vehicle sector and in other clean technologies. Further building on our platform within the circular economy and downstream markets is a key component of our strategy, underpinned by the sustainable development of the Songwe Hill rare-earths project in Malawi.”

I used to know John Neil at Unipart

Aston Martin Lagonda Global Holdings Plc 2.2% 3
DUNELM GROUP PLC 2.2% 2
HURRICANE ENERGY PLC 2.2% 2
INCHCAPE PLC 2.2% 2
LANCASHIRE HOLDINGS LTD 2.2% 2
SUPERGROUP PLC 2.2% 3
CYBG PLC 2.1% 2
GREENCORE GROUP PLC 2.1% 3
MICRO FOCUS INTERNATIONAL 2.1% 2
Galliford Try plc 2.0% 3

to be fair 2.2% isnt much in the scheme of things

Just need Bev and Shell man from Kerogen to not screw this up

written an email to complain to the board about Polygon and Kite

its actually DBAY advisors

DBAY Advisors Limited as discretionary investment manager of DouglasBay Capital III Fund LP

Well thats not a good sign

Sparkasse Bank Malta plc forms part of a larger Austrian Banking network. Our parent bank, Sparkasse Schwaz AG, is a member of the Austrian Savings Bank Group. Together with other Savings Banks the "Sparkasse" Brand is known to be one of Central Europe’s foremost Savings and Financial Services Group, with over 711 branch offices and 2.2 million customers in Austria alone.

taking the stake, theyve probably got a client who lives offshore in Malta

https://www.investegate.co.uk/card-factory-plc--card-/rns/holding-s--in-company/202006221650167048Q/

The queues outside TK Maxx were ridiculous

https://www.thegrocer.co.uk/discounters/bandm-sells-ffp2-face-masks-as-part-of-new-range/645544.article

22-Jun-20 15:29:27 25.80 81,164 Buy* 25.20 26.40 20.94k

I went to the high street today, Works was Open and it was RAMMED busy

dont think its as straightforward as that but I presume they will start receiving POA from Daewoo and Tata. theve probably been given a Corona booster bill loan also to help them.

Could be a great rise from here if they release the right RNS

I haven't bought any shares yet but i have just bought some clothes from Jacamo

cant make it up